Back to list

Randomized, double-blind, phase III clinical trial of neoadjuvant chemotherapy or a placebo in patients with triple-negative breast cancer followed by adjubant chemotherapy or a placebo

University of North Carolina at Chapel Hill


To determine if the usual chemotherapy given before surgery for breast cancer plus an experimental drug is better than the usual chemotherapy plus a placebo.


Cancer, Elderly, Older Adults, Women's Health


Drug or Biologic



18 - 99 years


Study Population

Male and Female participants 18 years and older diagnosed with invasive adenocarcinoma of the breast.


Jayadev Manikkam umakanthan

UNC Hospitals - UNCPN

For questions, contact:

Kerry Finch, RN, CCRP
(252) 962-4150
Visit Website

Recruitment Period End

June 7, 2027


Primary Location
NASH UNC Health Care Center
2460 Curtis Ellis Dr, Rocky Mount, NC 27804, USA

Study Qualifications

Gender Any

Age Range 18 - 99 years

Participant qualification(s) Patient must consent to participate. Diagnosed with invasive adenocarcinoma of the breast.

Not eligible if: Definitive clinical or radiologic evidence of metastatic disease. previous history of contralateral or ipsilateral invasive breast cancer. History of non-breast malignancies Cardiac disease that would preclude the use of the drugs included in the treatment regimens.

Number of Visits

    » 50 + In person visit(s)

    Screening, Clinic visits , Imaging

    » 0 Remote visit(s)

Participation Period

9 years


By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.